[Cisplatin (platidiame) in the treatment of patients with disseminated breast cancer].
In search of fresh indications for clinical application of cis-platinum, it was added to chemotherapy, the only treatment given to patients with disseminated breast cancer. The study group included 13 patients, with the data on 12 of them being subject to evaluation. The results showed a high antitumor effect of cis-platinum: objective remission was observed in 5 out of 12 cases (46.6%), with the complete 10 month-long remission included. All patients suffered from such untoward side-effects as sickness and vomiting. Moderate nephrotoxicity, which did not interfere with treatment, was registered in 3 cases. Since results confirmed the therapeutic effect of cis-platinum in breast cancer patients previously untreated with antitumor drugs further research into the problem should be recommended.